摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2,3,4-四氢-1,8-萘啶 | 13623-87-5

中文名称
1,2,3,4-四氢-1,8-萘啶
中文别名
——
英文名称
1,2,3,4-tetrahydro-1,8-naphthyridine
英文别名
1,2,3,4-Tetrahydro-[1,8]naphthyridin
1,2,3,4-四氢-1,8-萘啶化学式
CAS
13623-87-5
化学式
C8H10N2
mdl
MFCD08234598
分子量
134.181
InChiKey
ZCZVGQCBSJLDDS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    96 °C(Press: 0.6 Torr)
  • 密度:
    1.18±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.375
  • 拓扑面积:
    24.9
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    存储条件:2-8°C,避光,并保存在惰性气体中。

SDS

SDS:b22baae591033022d51792f51c1fe63f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1,2,3,4-Tetrahydro-1,8-naphthyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1,2,3,4-Tetrahydro-1,8-naphthyridine
CAS number: 13623-87-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10N2
Molecular weight: 134.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

1,2,3,4-四氢-1,8-萘啶是一种有机中间体,可通过在氩气手套箱中以叔丁醇钾和锰催化剂为助剂,在四氢呋喃溶剂中对1,8-萘啶进行氢化还原制得。该化合物可用于合成(E)-3-(5,6,7,8-四氢-1,8-萘啶-3-基)丙烯酸,这类化合物是Fab I抑制剂,并具有抗菌活性,因此适用于治疗哺乳动物,尤其是人类的细菌感染。

制备

在充满氩气的手套箱中,在4mL带有搅拌子的玻璃瓶中依次加入叔丁醇钾(5.6mg, 0.05mmol)、锰催化剂(0.005mmol)、四氢呋喃(0.5mL)和1,8-萘啶(0.25mmol),盖上瓶盖,并在瓶盖上插一个带有通气孔的针头(长为3cm,通气孔直径1mm)。将此玻璃瓶放入高压釜中。从手套箱取出高压釜后,用氢气置换三次(每次10bar),再充入80bar氢气,在120℃条件下反应16小时。

反应结束后,将高压釜置于冰水中冷却,小心释放高压气体,并取样进行GC定量分析和柱层析分离,最终得到目标产物。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,2,3,4-四氢-1,8-萘啶盐酸 、 palladium diacetate 、 lithium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 P(tolyl)3 、 溶剂黄146N,N-二异丙基乙胺lithium hexamethyldisilazane 作用下, 以 四氢呋喃1,4-二氧六环甲醇二氯甲烷 为溶剂, 反应 126.5h, 生成 (E)-3-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylic acid
    参考文献:
    名称:
    Indole Naphthyridinones as Inhibitors of Bacterial Enoyl-ACP Reductases FabI and FabK
    摘要:
    Bacterial enoyl-ACP reductase (FabI) is responsible for catalyzing the final step of bacterial fatty acid biosynthesis and is an attractive target for the development of novel antibacterial agents. Previously we reported the development of FabI inhibitor 4 with narrow spectrum antimicrobial activity and in vivo efficacy against Staphylococcus aureus via intraperitoneal. (ip) administration. Through iterative medicinal chemistry aided by X-ray crystal structure analysis, a new series of inhibitors has been developed with greatly increased potency against FabI-containing organisms. Several of these new inhibitors have potent antibacterial activity against multidrug resistant strains of S. aureus, and compound 30 demonstrates exceptional oral (po) in vivo efficacy in a S. aureus infection model in rats. While optimizing FabI inhibitory activity, compounds 29 and 30 were identified as having low micromolar FabK inhibitory activity, thereby increasing the antimicrobial spectrum of these compounds to include the FabK-containing pathogens Streptococcus pneumoniae and Enterococcus faecalis. The results described herein support the hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents.
    DOI:
    10.1021/jm0204035
  • 作为产物:
    描述:
    参考文献:
    名称:
    Koller; Kandler, Monatshefte fur Chemie, 1931, vol. 58, p. 234
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS ET COMPOSITIONS COMPRENANT DES INHIBITEURS DES CDK ET MÉTHODES DE TRAITEMENT DU CANCER
    申请人:UNIV GEORGIA STATE RES FOUND
    公开号:WO2010129858A1
    公开(公告)日:2010-11-11
    Disclosed herein are compounds suitable for use as antitumor agents, methods for treating cancer wherein the disclosed compounds are used in making a medicament for the treatment of cancer, methods for treating a tumor comprising, administering to a subject a composition comprising one or more of the disclosed cytotoxic agents, and methods for preparing the disclosed antitumor agents.
    本文披露了适用作抗肿瘤药剂的化合物,用于治疗癌症的方法,其中所披露的化合物用于制备治疗癌症的药物,治疗肿瘤的方法包括向受试者施用包含一种或多种所披露的细胞毒性药剂的组合物,以及制备所披露的抗肿瘤药剂的方法。
  • [EN] AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'AZADÉCALINE EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
    申请人:VIIV HEALTHCARE UK (NO 5) LTD
    公开号:WO2018002848A1
    公开(公告)日:2018-01-04
    Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula (I). These compounds are useful for the treatment of HIV and AIDS.
    具有药物和生物影响特性的化合物,其药物组合物和使用方法已列出。具体来说,提供了具有独特抗病毒活性的阿扎德卡林衍生物,作为HIV成熟抑制剂,如化合物(I)的公式所代表的那样。这些化合物对于治疗HIV和艾滋病是有用的。
  • [EN] AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'AZÉTIDIN-3-YLMÉTHANOL EN TANT QUE MODULATEURS DU RÉCEPTEUR CCR6
    申请人:IDORSIA PHARMACEUTICALS LTD
    公开号:WO2021219849A1
    公开(公告)日:2021-11-04
    The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.
    本发明涉及式(I)化合物,其合成以及作为CCR6受体调节剂用于治疗或预防各种疾病、状况或障碍。
  • [EN] Pan-Tropic Entry Inhibitors<br/>[FR] INHIBITEURS D'ENTRÉE PANTROPIQUE
    申请人:UNIV EMORY
    公开号:WO2019183133A1
    公开(公告)日:2019-09-26
    This disclsore relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.
    本公开涉及按照式(I)的化合物、盐、前药和含有该化合物的药物配方,用于治疗与CXCR4和CCR5相关的疾病。这些疾病可能包括病毒感染、异常细胞增殖、视网膜退化和炎症性疾病,或者这些化合物可以用作免疫刺激剂或免疫抑制剂。此外,这些化合物可以与另一种来自抗病毒药物或化疗药物的活性成分结合使用。
  • [EN] AZOLE COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS D'AZOLE UTILISÉS EN TANT QU'INHIBITEURS DES PIM
    申请人:AMGEN INC
    公开号:WO2012129338A1
    公开(公告)日:2012-09-27
    The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    该发明涉及公式I和Ia的双环化合物及其盐。在某些实施例中,该发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中,该发明涉及包含本文所披露的化合物的药物组合物,以及它们在预防和治疗Pim激酶相关疾病和病症,尤其是癌症中的用途。
查看更多